CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering – FirstWord Pharma

Written by

admin

in

  1. CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering  FirstWord Pharma
  2. Scientists have edited a gene that may reduce high cholesterol permanently  

Continue Reading

More posts